{"name":"Tracon Pharmaceuticals Inc.","slug":"tracon-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":12045000,"revenueGrowth":0,"grossMargin":0,"rdSpend":12277000,"netIncome":-3588000,"cash":10105000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"TRC253","genericName":"TRC253","slug":"trc253","indication":"Other","status":"phase_1"},{"name":"TRC105 chimeric anti-CD105 antibody","genericName":"TRC105 chimeric anti-CD105 antibody","slug":"trc105-chimeric-anti-cd105-antibody","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Votrient","genericName":"Votrient","slug":"votrient","indication":"Renal cell carcinoma","status":"marketed"}]}],"pipeline":[{"name":"TRC253","genericName":"TRC253","slug":"trc253","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Votrient","genericName":"Votrient","slug":"votrient","phase":"marketed","mechanism":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B","indications":["Renal cell carcinoma","Sarcoma of soft tissue"],"catalyst":""},{"name":"TRC105 chimeric anti-CD105 antibody","genericName":"TRC105 chimeric anti-CD105 antibody","slug":"trc105-chimeric-anti-cd105-antibody","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQckpPUldMdjR0RTFmWjRtTWF0Mmtqc1ZoZklERVA2QzlQRk1nYlBPbmd4ZHN4SDdubElXSWhDS1Jzd0NzOFhuVEpvTjY1MzlzLWNVdV9XSE5kekFVMWV2TWxMYmZrdG5JYl9HS0dGZkpxV0JuSnJ2dUdoaDhlT3Z0Y25KbFR6aE9yb1ZzRHlDaUpTemUzM0dWMm5tX3Z5eGZjMnBKa19rMHRQaFRUWWNkMW9qS3laZTdJenBWYkxOVktoM1JFeUFrTnhWQ3NUQ0h4Z3ctdl9sai1qVjNqb2Exd1U1dlpnYkhkUzRjeS1lanVQSDVLQ2pxZE95V2tSc25Hcl9xWFU1VHFZaUhUUDM2RjR0Y19XNjVKMFFkVA?oc=5","date":"2025-11-27","type":"pipeline","source":"PR Newswire","summary":"Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight - PR Newswire","headline":"Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pip","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPNjJBXzE5X0pwT3BfalJmLUZ4djRzczM5UEFnWldGSzl6Mkl3Rl81M09wODBaaFBmczNDNkxMWS1Ib05SeV9hUS0zLVZGc05LcnJHYk5OMk9MS3RGVDBKMVR1M1ZhRjdyMVdsbloxYzVnaTJiVlZaaDlfVThseFpSVDRnelUwLVUtUERIVEo5ZUV5b1daclQ2T2d0eFlkWWJaY2dSNWNIcWJsTmdvMDlzdUFacTZ5czczX19CX1dvbS13OV9wZ0lxOHBNWXYtc0RhWXNQNjlBdGpzaGZ4eklUQmNIX3Q3ZXN2ejczZzNlSHo4YWg5aVcyeDBYUjktdlE?oc=5","date":"2025-10-20","type":"pipeline","source":"PR Newswire","summary":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight - PR Newswire","headline":"Liposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - PR Newswire","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5tc2QtNkF4MmhyYmxsanZhR3k4Z2tkQ0s1cXVJT1B0d280LVJCMUllQWE1LXF3enlLV05VN1lxc0FYTHNla2JVUGQ5c294WFBGQ0Vn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KAPA Stock Price, News & Analysis - Stock Titan","headline":"KAPA Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE1QZWc4aC1ybDZQY1FqRUFKRFl3bWozSjNjMlFoZmZHWkFjZDIwV0ZiYS1pYUNpUUV1TGRpY19SV1ZFUWVReU8xVjJiU3JYazBpVXM2Z1pCV1VoZEpGYko0X3R2aDhsYk1oSWRqS3k4TFpJR2dTanIw?oc=5","date":"2024-10-31","type":"pipeline","source":"Fierce Biotech","summary":"The 2024 Biotech Graveyard - Fierce Biotech","headline":"The 2024 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQQkxJUWxRN2EyN2dGMDBRN3ZCX3BRTUhyUkNJLTRzNEJnRjVOVzhZSDI5MjNFU0phRHJBUTVHdVRTMkZjR1R4VG1GZTB5bmZkdHBDQWgyQXJNdG1oZXR6TTBkdVZsVVMyOHpWUzJuSTgxVmw2V0dQQ2pDUmpVM2NlbVY2cGJGNGQ0VEplZHk2ZjlGdURoUlVDeHltZFhhRTVRLVVQNHpRVlU0d0VDV0w4V0Vqb2o2eFpDcGhlWG81aDVDVVFMU2ZtdENvR0Y4bnFzRGVj?oc=5","date":"2024-07-30","type":"pipeline","source":"GlobeNewswire","summary":"TRACON Pharmaceuticals Announces it Will Wind Down Operations - GlobeNewswire","headline":"TRACON Pharmaceuticals Announces it Will Wind Down Operations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOV0hzT3N1dk10djRZX3Y1TGlNVWhFUGlQWGxvS2VqaHJQekNwQ3NmMnJUUTRXaUJrZjg2ejl4UUJ1aUFKOGhQRm9wOFpyT2hYNUVXdmlfN2NzLWxqb2k5bnM0d2NWX3N0QlRRWGFBRkdfOUI5V2Y2SGdnMlR4bHZ4SE50amdTQ3hXVXVFUHIyODcwNWcwa1E4Z29wbktCaTI4QTVFSFFKekU?oc=5","date":"2024-07-02","type":"trial","source":"BioWorld News","summary":"Tracon quits work on anti-PD-L1 envafolimab after phase III flop - BioWorld News","headline":"Tracon quits work on anti-PD-L1 envafolimab after phase III flop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNNVk4OUtYOXlVTjQxWGdlSjVzNF8tVXh1cjdFOEZaeXNnblAzV0kyVlBRRTB4Vl9neW43S1JrLVBqcXllM1lzZjVUbEFaWlJ2a3lwdTJwR0x1QlBXTGgzazY4QXlnZkRXaEJHbE1jMGRnczFRdVA1Qlc5VjVEVFJlY2h4R3hmTXFRaWhzMGNxYUh3VVpzc2paVjZSU0l1c1J0?oc=5","date":"2024-07-01","type":"trial","source":"Yahoo Finance","summary":"TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform - Yahoo Finance","headline":"TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQN1JxRkVKUVJaVmFFSGE5SThBM0t4aWFaQzhWWkRaLXNNTzRPS1pXT0kxUnBUaXBKYTdKTHpKc1BwTFVKWXJkQjJnMUNSS19qN1lJSE5RTkJfYktQa1ZkZXBiUUh5M01fU1MxcHFlS3JJOVo0ZWlmaW9xTkJtMUs4MkVEd0FWYUwwOEtfZWJlaWhsZW1ScFJxNHJncXlfQUpfbHhtX05zR2kyQWktLV9HVm9FSGR5amJqYUtCYm4wVU9NSU42WkVIMXNoYmgyRlE2VFRrMnRxS1duTFdYNE1meDBLLVdoQTlSZGJjQjB6ZC1RUmpfbDFlcm11X0NMNlRsaVNmdzZLSE1wYjJM?oc=5","date":"2023-11-20","type":"deal","source":"GlobeNewswire","summary":"TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment - GlobeNewswire","headline":"TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE0yS3JSUl9PNkc0TjFORk5SZ1RNdzcwSWR6STJVSHlqSmtSXy15Q1U4X1RBTC1VdW5Pa190djZXeGpPVjQwNV9vbzF0SjlMbU80SE55bWI1NDVVcGhYZFRTX0JXVWxUc002LVJSRVF6ZjBReUE4ZGFPRkV3ZXpFZw?oc=5","date":"2022-08-11","type":"pipeline","source":"proactiveinvestors.com","summary":"TRACON Pharmaceuticals Inc Share Price - TCON, RNS News, Articles, Quotes, & Charts (NASDAQ:TCON) - proactiveinvestors.com","headline":"TRACON Pharmaceuticals Inc Share Price - TCON, RNS News, Articles, Quotes, & Charts (NASDAQ:TCON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQME1IbzhlanpsWmg0NFhpTXdyQjRRcWQzR1luVGRSbklfY3I0R2VsS0xjeFVfYkIwX0xXbFNxNldhZXNtSURDR0gzQmVTdDQ2Q3c0bTR6TWxIc3FPa0I0ejBjXzVGeExwVmF6bVl6ZHZZZmZxcVhsdGFMQWlkTnRWdzlBNWZMOFlCcDNqb05OcVhSUlF3VVhzcXBRS2xCN19nMXdrazdDTy1VSXlMWW9wTWIxNGVpNVI3UDk5Umtzcm0wc3dacS1CV25DZjBkNkR2eTNKd3REWFE5NDA?oc=5","date":"2020-12-29","type":"pipeline","source":"GlobeNewswire","summary":"TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering - GlobeNewswire","headline":"TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ZVlV5Q1NiM0puQm5UZ25ZSG1iTlRSMDhTQkx1bVBzcF9nUWdqQkRtUDRQcHNUTXprWlRXV25LTm1mYmlFRzd6MFV0dVA5RDVnVGoxUi01M2dtNkQ2dWRz?oc=5","date":"2020-01-06","type":"pipeline","source":"ChartMill","summary":"TCON Stock Price, Quote & Chart | TRACON PHARMACEUTICALS INC (NASDAQ:TCON) - ChartMill","headline":"TCON Stock Price, Quote & Chart | TRACON PHARMACEUTICALS INC (NASDAQ:TCON)","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":12045000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":12045000,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"},{"value":346000,"period":"2021-12-31"},{"value":346000,"period":"2021-12-31"},{"value":346000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":12277000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-3588000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":10105000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}